CONCLUSIONS — In the present
study, we found that the lipase inhibitor
orlistat was superior to placebo in maintaining
an initial weight loss induced by a
VLED for 3 years in subjects who were at
high risk of cardiovascular diseases due to
abdominal obesity and impaired fasting
glucose/diabetes or dyslipidemia. This extra
weight loss maintenance obtained
with orlistat was associated with reduced
development of type 2 diabetes. The
VLED effectively induced a major weight
loss of 14 kg after 8 weeks, and this
weight loss was associated with pronounced
improvements in all metabolic
risk factors.